What Optellum and RapidAI Announced About Virtual Nodule Clinic on the Rapid Enterprise Platform

Optellum said on 20 October 2026 that its Virtual Nodule Clinic, including its Lung Cancer Prediction AI, had been integrated with the RapidAI Rapid Enterprise Platform. Optellum describes Virtual Nodule Clinic as combining patient discovery AI that identifies lung nodules in radiology reports, workflow tools for tracking those patients, and the Lung Cancer Prediction model that scores how likely a nodule is to be cancer. The company says the combination helps care teams prioritise patients and reduce patients lost to follow up. Optellum also describes the product as the first FDA cleared and Medicare reimbursed AI solution for image based lung cancer risk stratification, reimbursed under CPT codes 0721T and 0722T. Johnathan Watkins, chief executive of Optellum, is quoted saying the collaboration makes Virtual Nodule Clinic available to the many health systems that already rely on the Rapid Enterprise Platform. No customer, contract value or launch date is named.

Why the Optellum and RapidAI Integration Matters to Health System Buyers

Distribution is the quiet problem in healthcare AI. A tool can be cleared, reimbursed and genuinely good and still sell slowly, because every hospital is a separate security review, a separate integration and a separate budget line. Riding into the building on a platform the hospital already trusts skips most of that, which is why this kind of deal moves more revenue than a new feature usually does. It cuts the other way too: Optellum now depends on another company for reach, and platform relationships get renegotiated. Two claims deserve care. The reimbursement point is real and unusual, because a paid CPT code means a hospital can bill for the work rather than absorb it, but Optellum is the one making the first-in-market claim and nobody has independently checked it. And reducing patients lost to follow up is the outcome worth having, yet the announcement names no site and no number that shows it happened.

Where the Optellum Update Comes From

Optellum is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Optellum original source.

How We Would Research the Optellum and RapidAI Integration

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would start by asking a health system already running the Rapid Enterprise Platform what turning this on actually required, because the value of the deal is entirely in how little work it saves them.
  2. Then we would check the CPT reimbursement claim against a payer policy rather than the announcement, since a code existing and a payer paying it are different facts.
  3. We would ask Optellum for a site that measured patients lost to follow up before and after, because that is the number the product is sold on.